Travere Therapeutics, Inc. TVTX
Set alert
49.26 USD -1.13 -2.24%
At close
47.00 -2.26 -4.59%
Pre-market · Nov 3, 8:10 AM ET
48.64 Day range 52.87
22.59 52-week range 68.73
- YTD
- +28.92%
- 1 year
- +42.66%
- Open
- 50.47
- Prev close
- 50.39
- Mkt cap
- 4.58B
- Vol
- 2.91M
- Avg vol
- 1.79M
- EPS
- -0.74
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 48.64
- High
- 52.87
- Forward P/E
- 9.14
- Beta
- 1.12
- Short ratio
- 5.59
- Inst. own
- 116.11%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 18, 2027
- 50-d avg
- 59.06
- 200-d avg
- 46.62
- 1y target
- 75.21
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 75.21 +52.7% upside
Now 49.26
- Target (low)
- 62.00
- Target (mean)
- 75.21
- Target (high)
- 90.00
Ratings (0m) 15 14 buy · 1 hold · 0 sell
- Strong buy2
- Buy12
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 15
- 1 month ago 15
- 2 months ago 15
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.41736 | -0.57108 – 0.71 | 0.59 | -29.3% | 195.29M | +18.5% | 8 |
| Next quarter | 0.93141 | 0.65 – 1.22 | 0.37 | +151.7% | 231.72M | +78.7% | 8 |
| Current year | 1.45 | 0.96241 – 2.51 | 0.91 | +59.1% | 723.77M | +47.5% | 8 |
| Next year | 5.39 | 3.50 – 6.76 | 1.45 | +272.4% | 1.08B | +48.7% | 8 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 24, 2026 | Guggenheim | Maintained | Buy | Buy |
| Sep 22, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Sep 22, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 10, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Aug 6, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 6, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Aug 5, 2026 | TD Cowen | Maintained | Buy | Buy |
| Aug 5, 2026 | Citigroup | Maintained | Buy | Buy |
| Aug 5, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Aug 5, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jul 30, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Jun 25, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jun 22, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jun 18, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Jun 15, 2026 | Citigroup | Maintained | Buy | Buy |
| Jun 12, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Jun 3, 2026 | Citigroup | Maintained | Buy | Buy |
| Jun 3, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Jun 2, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 6, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| May 5, 2026 | TD Cowen | Maintained | Buy | Buy |
| May 5, 2026 | Citigroup | Maintained | Buy | Buy |
| May 5, 2026 | Wedbush | Maintained | Outperform | Outperform |
| May 5, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 24, 2026 | Guggenheim | Maintained | Buy | Buy |
| Apr 14, 2026 | Citigroup | Maintained | Buy | Buy |
| Apr 14, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Apr 14, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Apr 14, 2026 | Guggenheim | Maintained | Buy | Buy |
| Apr 14, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |